Literature DB >> 12481409

The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity.

Andreas Vogt1, Katharine E Pestell, Billy W Day, John S Lazo, Peter Wipf.   

Abstract

Phospholipids and lipid second messengers mediate mitogenic signal transduction and oncogenesis, but there have been few successful examples of small molecules that affect biologically important phospholipid metabolism. Here we investigated the actions of a previously described antitumor agent, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid (SC-alpha alpha delta 9), which has antisignaling properties, on phospholipases. Although SC-alpha alpha delta 9 had been shown to be a potent and selective inhibitor of the Cdc25 family of dual-specificity phosphatases, many of its cellular effects are not readily reconciled with phosphatase inhibition. Molecular modeling studies suggested that SC-alpha alpha delta 9 shared several structural features with membrane phospholipids. Enzyme inhibition studies in vitro revealed that SC-alpha alpha delta 9 was a potent inhibitor of phospholipase C (PLC; IC50 = 25 microM) but did not inhibit phospholipase D activity at concentrations up to 100 microM. In H-ras (Q61L)-transformed Rat-1 fibroblasts with constitutively elevated levels of phosphorylated extracellular signal-regulated kinase (Erk), SC-alpha alpha delta 9 inhibited both proliferation and oncogenic Erk activation at concentrations that inhibited PLC in vitro. A SC-alpha alpha delta 9 congener that lacked antiproliferative activity also did not inhibit PLC in vitro. In the PLC-dependent scratch wound healing model, SC-alpha alpha delta 9 was 10-fold more potent than the phosphatidylcholine-specific PLC inhibitor D-609. We propose that the structural resemblance of SC-alpha alpha delta 9 to phospholipids allows it to inhibit cellular PLC, thereby providing a possible molecular mechanism for SC-alpha alpha delta 9's effects on oncogenic Erk activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481409

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  5 in total

1.  Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.

Authors:  Masanao Nakashima; John S Lazo
Journal:  J Pharmacol Exp Ther       Date:  2010-05-19       Impact factor: 4.030

Review 2.  Choline metabolism in malignant transformation.

Authors:  Kristine Glunde; Zaver M Bhujwalla; Sabrina M Ronen
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

3.  Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors.

Authors:  Lívia B Salum; Wanessa F Altei; Louise D Chiaradia; Marlon N S Cordeiro; Rafael R Canevarolo; Carolina P S Melo; Evelyn Winter; Bruno Mattei; Hikmat N Daghestani; Maria Cláudia Santos-Silva; Tânia B Creczynski-Pasa; Rosendo A Yunes; José A Yunes; Adriano D Andricopulo; Billy W Day; Ricardo J Nunes; Andreas Vogt
Journal:  Eur J Med Chem       Date:  2013-03-06       Impact factor: 6.514

4.  Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.

Authors:  Luisa Paris; Serena Cecchetti; Francesca Spadaro; Laura Abalsamo; Luana Lugini; Maria Elena Pisanu; Egidio Iorio; Pier Giorgio Natali; Carlo Ramoni; Franca Podo
Journal:  Breast Cancer Res       Date:  2010-05-12       Impact factor: 6.466

5.  A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods.

Authors:  Justin C Yarrow; Zachary E Perlman; Nicholas J Westwood; Timothy J Mitchison
Journal:  BMC Biotechnol       Date:  2004-09-09       Impact factor: 2.563

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.